CTLA4 and nonpapillary renal cell carcinoma: IMmotion010 is evaluating 12-month adjuvant therapy with PD-L1 inhibitor atezolizumab, PROSPER neoadjuvant therapy (nivolumab two doses), followed by 9-month adjuvant therapy with PD-1 inhibitor nivolumab and CheckMate 914 6-month adjuvant therapy with the combination of CTLA-4 inhibitor ipilimumab and PD-1 inhibitor nivolumab in resected localized ccRCC patients, and RAMPART 12-month durvalumab adjuvant therapy and 12-month adjuvant CTLA-4 and PD-L1 inhibitor (tremelimumab and durvalumab) combination therapy.